DIAGNOS Updates Health Canada Licence Application for AI-Powered CARA System

Event summary

  • DIAGNOS submitted a modified Class II medical device licence application for its CARA System platform to Health Canada on June 16, 2026.
  • The submission follows detailed guidance from Health Canada in fall 2025, incorporating advanced image analysis capabilities.
  • CARA System includes modules for image enhancement, AMD detection, diabetic retinopathy, and myopic vascular anomalies.
  • DIAGNOS claims strict adherence to Health Canada's frameworks, anticipating a positive regulatory outcome.

The big picture

DIAGNOS's updated submission reflects the increasing scrutiny and guidance from Health Canada on AI-powered medical devices. The approval, if granted, would position DIAGNOS as a key player in AI-enhanced eye care diagnostics, competing with other digital health innovators targeting early disease detection. The strategic move aligns with broader industry trends toward integrating AI into clinical workflows to improve diagnostic accuracy and efficiency.

What we're watching

Regulatory Timing
Whether Health Canada's review process will result in approval within expected timeframes, given the modified submission.
Market Adoption
How optometrists will integrate AI-powered diagnostic tools into existing workflows if CARA receives approval.
Competitive Positioning
The pace at which DIAGNOS can differentiate itself in the growing AI diagnostics market post-approval.